Cargando…

Cost-effectiveness of bazedoxifene versus raloxifene in the treatment of postmenopausal women in Spain

BACKGROUND: The purpose of this study was to assess the cost-effectiveness of bazedoxifene and raloxifene for prevention of vertebral and nonvertebral fractures among postmenopausal Spanish women aged 55–82 years with established osteoporosis and a high fracture risk. METHODS: A Markov model was dev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Darbà, Josep, Pérez-Álvarez, Nuria, Kaskens, Lisette, Holgado-Pérez, Susana, Racketa, Jill, Rejas, Javier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709644/ https://www.ncbi.nlm.nih.gov/pubmed/23882153 http://dx.doi.org/10.2147/CEOR.S42755

Ejemplares similares

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain
por: Darbà, Josep, et al.
Publicado: (2015)

Disability-adjusted-life-years losses in postmenopausal women with osteoporosis: a burden of illness study
por: Darbà, Josep, et al.
Publicado: (2015)

Relationship between patient dependence and direct medical-, social-, indirect-, and informal-care costs in Spain
por: Darbà, Josep, et al.
Publicado: (2015)

Future projections of opioid use and cost in patients with chronic osteoarthritis pain in Spain
por: Rejas-Gutierrez, Javier, et al.
Publicado: (2021)

Bazedoxifene for the prevention of postmenopausal osteoporosis
por: Gennari, Luigi, et al.
Publicado: (2008)

Efficacy and safety of bazedoxifene for postmenopausal osteoporosis
por: Kawate, Hisaya, et al.
Publicado: (2011)

Budget impact analysis of the fentanyl buccal tablet for treatment of breakthrough cancer pain
por: Darbà, Josep, et al.
Publicado: (2013)

Disability-adjusted life years lost due to diabetes in France, Italy, Germany, Spain, and the United Kingdom: a burden of illness study
por: Darbà, Josep, et al.
Publicado: (2015)

Incorporating bazedoxifene into the treatment paradigm for postmenopausal osteoporosis in Japan
por: Ohta, H., et al.
Publicado: (2014)

Bazedoxifene, a Postmenopausal Drug, Acts as an Antimalarial and Inhibits Hemozoin Formation
por: Sudhakar, Renu, et al.
Publicado: (2022)

Pharmacogenomics Study for Raloxifene in Postmenopausal Female with Osteoporosis
por: Lu, Hsing-Fang, et al.
Publicado: (2020)

Patient characteristics and hospitalisation costs of spinal muscular atrophy in Spain: a retrospective multicentre database analysis
por: Darbà, Josep, et al.
Publicado: (2019)

Modeling the Annual Costs of Postmenopausal Prevention Therapy: Raloxifene, Alendronate, or Estrogen-Progestin Therapy
por: Mullins, C. Daniel, et al.
Publicado: (2003)

Analysis of the management and costs of headache disorders in Spain during the period 2011–2016: a retrospective multicentre observational study
por: Darbà, Josep, et al.
Publicado: (2020)

Effect of Raloxifene Treatment on Osteocyte Apoptosis in Postmenopausal Women
por: van Essen, Huib W., et al.
Publicado: (2007)

Characteristics, management and medical costs of patients with depressive disorders admitted in primary and specialised care centres in Spain between 2011 and 2016
por: Darbà, Josep, et al.
Publicado: (2020)

Efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: A systematic review and meta-analysis
por: Peng, Lihua, et al.
Publicado: (2017)

Cost-effectiveness of raloxifene in the treatment of osteoporosis in Chinese postmenopausal women: impact of medication persistence and adherence
por: Chen, Mingsheng, et al.
Publicado: (2016)

The cost of lost productivity due to premature lung cancer-related mortality: results from Spain over a 10-year period
por: Darbà, Josep, et al.
Publicado: (2019)

Comparative evaluation of raloxifene versus estrogen: Progestin on symptomatology, endometrium, and lipid profile in postmenopausal women
por: Dogiparthi, Anuradha, et al.
Publicado: (2010)

Treating postmenopausal osteoporosis in women at increased risk of fracture – critical appraisal of bazedoxifene: a review
por: Vestergaard, Peter, et al.
Publicado: (2010)

88116 Effect of conjugated estrogens and bazedoxifene on glucose, energy and lipid metabolism in obese postmenopausal women
por: Marlatt, Kara, et al.
Publicado: (2021)

Alendronate versus Raloxifene for Postmenopausal Women: A Meta-Analysis of Seven Head-to-Head Randomized Controlled Trials
por: Lin, Tiao, et al.
Publicado: (2014)

The Effects of Bazedoxifene on Bone, Glucose, and Lipid Metabolism in Postmenopausal Women With Type 2 Diabetes: An Exploratory Pilot Study
por: Yoshii, Taishi, et al.
Publicado: (2015)

Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer
por: Torrisi, R, et al.
Publicado: (2001)

Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update
por: Messalli, Enrico M, et al.
Publicado: (2010)

Effects of minodronate in postmenopausal women with osteoporosis who received prior treatment with raloxifene
por: Toda, Aska, et al.
Publicado: (2017)

Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women
por: Ha, J., et al.
Publicado: (2022)

Quality of life and patient satisfaction with raloxifene/cholecalciferol combination therapy in postmenopausal women
por: Lee, Dong-Yun, et al.
Publicado: (2022)

Epidemiology and management of parathyroid gland disorders in Spain over 15 years: A retrospective multicentre analysis
por: Darbà, Josep, et al.
Publicado: (2020)

Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: a post hoc cost-effectiveness analysis in usual medical practice in Spain
por: De Salas-Cansado, Marina, et al.
Publicado: (2012)

Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis
por: Sicras-Mainar, A., et al.
Publicado: (2018)

Results after 10 years of colorectal cancer screenings in Spain: Hospital incidence and in-hospital mortality (2011–2016)
por: Darbà, Josep, et al.
Publicado: (2020)

Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis
por: Christiansen, Claus, et al.
Publicado: (2010)

Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia)
por: Fujiwara, Saeko, et al.
Publicado: (2014)

Effectiveness of Osteoporosis Drug in Postmenopausal Women with Spinal Compression Fracture: Combined Consecutive Therapy of Teriparatide and Raloxifene versus Bisphosphonate Single
por: Shin, Chang Jin, et al.
Publicado: (2016)

Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain
por: Romero-Gomez, Manuel, et al.
Publicado: (2020)

Early versus later response to treatment in patients with community-acquired pneumonia: analysis of the REACH study
por: Blasi, Francesco, et al.
Publicado: (2014)

Current status and direct medical cost of amyotrophic lateral sclerosis in the region of Catalonia: A population-based analysis
por: Darbà, Josep
Publicado: (2019)

Evaluation of insulin-like growth factor-I in postmenopausal women with breast cancer treated with raloxifene
por: da Silva, Benedito B, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_ov16bdjvkbi6h68d48r46rq022